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Subcutaneous (SC) and visceral (VIS) obesity are
associated with different risks of diabetes and the
metabolic syndrome. To elucidate whether these
differences are due to anatomic location or intrinsic
differences in adipose depots, we characterized
mice after transplantation of SC or VIS fat from donor
mice into either SC or VIS regions of recipient mice.
The groupwith SC fat transplanted into the VIS cavity
exhibited decreased body weight, total fat mass, and
glucose and insulin levels. These mice also exhibited
improved insulin sensitivity during hyperinsulinemic-
euglycemic clamps with increased whole-body glu-
cose uptake, glucose uptake into endogenous fat,
and insulin suppression of hepatic glucose produc-
tion. These effects were observed to a lesser extent
with SC fat transplanted to the SC area, whereas
VIS fat transplanted to the VIS area was without
effect. These data suggest that SC fat is intrinsically
different from VIS fat and produces substances that
can act systemically to improve glucosemetabolism.
INTRODUCTION
While the association between obesity and type 2 diabetes is
well known, the site of fat accumulation in humans can play a
pivotal role in these health risks. Central obesity, characterized
by increased amounts of intra-abdominal fat, is associated
with insulin resistance, high risk of type 2 diabetes, dyslipidemia,
accelerated atherosclerosis, and mortality (Carey et al., 1997;
Wang et al., 2005; Nicklas et al., 2006; Ross et al., 2007). By con-
trast, peripheral obesity, i.e., increased amounts of subcutane-
ous fat, especially in the gluteofemoral regions, is associated
with improved insulin sensitivity and a lower risk of developing
type 2 diabetes, dyslipidemia, and atherosclerosis in compari-
son to levels associated with central obesity (Misra et al., 1997;
Snijder et al., 2003; Tanko et al., 2003). Consistent with this no-
tion that visceral fat produces adverse metabolic effects, omen-
tectomy, i.e., removal of visceral fat, results in decreased insulin
and glucose levels in humans (Thorne et al., 2002), whereas
removal of subcutaneous fat by liposuction does not result in im-
provement in any aspect of the metabolic syndrome (Klein et al.,
2004). Also, in general, diet and/or exercise result in improved
insulin sensitivity, and this is associated with a greater loss of410 Cell Metabolism 7, 410–420, May 2008 ª2008 Elsevier Inc.visceral fat than subcutaneous fat (Langendonk et al., 2006;
Gan et al., 2003).
Rodents also show differences in fat distribution and insulin
resistance. Mice on diets high in saturated fat, mice with genetic
defects in leptin signaling, and mice during normal aging exhibit
increased amounts of fat, especially in intra-abdominal depots,
and are insulin resistant (Rebuffe-Scrive et al., 1993; Dubuc,
1976; Barzilai et al., 1998). As in humans, omentectomy in obese
mice results in improved insulin action and reduced hepatic glu-
cose production (Gabriely et al., 2002). However, removal of
subcutaneous fat in obese Zucker rats results in no consistent
beneficial changes in weight gain, serum glucose, or insulin
levels (Liszka et al., 1998). Thus, both human and rodent studies
suggest that increased visceral fat, but not removal of peripheral
fat, has adverse effects on metabolism and disease outcome.
The most likely mechanism for these metabolic differences
between central and peripheral obesity is that adipokines, free
fatty acids, and other metabolites released from visceral fat drain
into the portal circulation, where they can exert adverse effects
on hepatic and other tissuemetabolism (Kabir et al., 2005). How-
ever, several findings suggest that this may be an oversimplifica-
tion. First, in lipoatrophic diabetes there is a loss of both visceral
and subcutaneous fat, and this is associated with severe insulin
resistance, hyperlipidemia, and glucose intolerance (Capeau
et al., 2005). Second, assessment of insulin sensitivity in humans
with visceral obesity has shown lower levels of insulin resistance
in individuals that also have subcutaneous obesity, suggesting
perhaps some beneficial effect of subcutaneous fat in addition
to the adverse effects of visceral fat (Misra et al., 1997; Snijder
et al., 2003; Tanko et al., 2003). This notion is also consistent
with the effects of thiazolidinedione treatment, which improves
insulin sensitivity despite increasing total body fat mass by pri-
marily increasing the subcutaneous fat depot (Miyazaki et al.,
2002). Third, when obese ob/obmice are engineered to overex-
press adiponectin in adipose tissue, there is a massive further
increase in subcutaneous fat, and this is associated with im-
proved insulin sensitivity with decreased glucose and insulin
levels, increased lipid clearance, improved diacylglycerol levels
and histology of the liver, and fully functional healthy b cells
(Kim et al., 2007). Likewise, increasing subcutaneous fat by
transplanting visceral fat to the subcutaneous area of lipoatro-
phic mice improves their metabolic profile rather than making it
worse (Gavrilova et al., 2000). These observations suggest that
while visceral fat may have adverse effects, subcutaneous fat
may actually have some beneficial effects on metabolism.
Studies of gene expression in subcutaneous and visceral fat in
both rodents and humans show major differences in patterns of
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our laboratory has shown that whole fat tissue as well as adipo-
cytes and preadipocytes from subcutaneous and intra-abdomi-
nal depots in both rodents and humans demonstrates major
differences in expression of developmental and patterning
genes, suggesting that adipose tissues in these depots may
even have differing developmental lineage (Gesta et al., 2006).
In addition to their intrinsic properties, fat cells are also exposed
to different extrinsic factors, such as the effects of hormones and
growth factorsacting inaparacrine fashion,neuronal innervations,
interactionwithothercells in thesurrounding tissue, sitesof vascu-
lar drainage, supplyof variousnutrients, and levelsof oxygenation.
This raises the question: Are themetabolic effects associatedwith
visceral fat versus subcutaneous fat due to anatomic location or to
cell-autonomous differences between these adipose depots?
In the current study, we explored this question by using a fat
transplantation strategy in which we transplanted either visceral
(intra-abdominal) or subcutaneous fat from donor mice into
either visceral or peripheral subcutaneous regions of recipient
mice and examined the effects of this addition to these fat de-
pots on both whole-body and cellular metabolism. Somewhat
surprisingly, we found that the major effects on metabolism
and body weight were beneficial effects of added subcutaneous
fat rather than a detrimental effect of added visceral fat and that
these effects were greatest when subcutaneous fat was placed
in an intra-abdominal site. This suggests that fat cells in different
depots have intrinsically different properties and that these may
be detrimental as well as beneficial.
RESULTS
Body Weight, Body Composition, and Energy Balance
Fat transplantations were performed using either subcutaneous
(SC) flank fat or visceral (VIS) epididymal fat of donor mice and
placing the fat grafts into either the dorsal subcutaneous area
or the intra-abdominal area of 12-week-old wild-type C57BL/6
recipient mice (Figure 1). The donor mice were wild-type
C57BL/6 mice in cohort 1, whereas they were C57BL/6 mice
transgenic for green fluorescent protein (GFP) expressed on
the b-actin promoter (Actb) in cohort 2. During the 12weeks after
surgery, mice in the sham group had steady body weight gain in
cohorts 1 and 2. In mice in which visceral fat was added to the
visceral cavity (VIS-VIS group), total body weight gained at the
end of the study was 108% of that in the sham group in cohort
1 and 88% of that in the sham group in cohort 2 but was not sig-
nificantly different from either sham group (Figures 2A and 2B). In
the groupwith visceral fat transplanted to the subcutaneous area
(VIS-SC group), body weight was not significantly different from
the sham group and was not studied further. In contrast, when
SC fat was transplanted to the SC area (SC-SC group), there
was a significant slower increase in body weight, and by 12
weeks, this group had 85% and 84% of the weight gained by
the sham group in cohorts 1 and 2, respectively. More striking
was the effect of adding SC fat to the VIS cavity (SC-VIS group),
which had the greatest impact on reducing the rate of weight
gain. By the end of the 12 week study period, mice in the
SC-VIS group had gained on average 63% of the amount gained
by the sham group in cohort 1 and 59% of the weight gained by
the sham group in cohort 2 (p < 0.05). Thus, increasing theamount of SC fat by transplantation resulted in decreased
subsequent weight gain, and this effect was greatest when SC
fat was added to the VIS cavity.
These differences in weight gain between the sham and trans-
plantation groupswere due primarily to differences in fat mass as
measured by dual-energy X-ray absorptiometry (DEXA) scan.
Total fat mass was similar among the sham, VIS-VIS, and
VIS-SC groups; was decreased by 18% in the SC-SC group
(p < 0.05); and was reduced by about 54% in the SC-VIS group
(p < 0.01) at the end of the study (Figure 2C). Note that this pat-
tern was similar to that of the body weight decrease in the same
groups. Percent body fat, i.e., fat mass divided by total body
weight, showed a similar decreasing pattern among the groups,
with highest percent body fat in the sham, VIS-VIS, VIS-SC, and
SC-SC groups and a significant 46% reduction in the SC-VIS
group (p < 0.01) (Figure 2D). Absolute lean body mass was sig-
nificantly higher in the SC-VIS group than the sham group at 6
and 8 weeks and tended to be higher at 12 weeks (Figure 2E),
but in relation to body weight, percent lean mass was highest
in the SC-VIS group in comparison to the sham group (Figure 2F).
The difference in body weight gain was not due to differences
in food intake. Food intake measured at 10 weeks after trans-
plantation by the Comprehensive Lab Animal Monitoring System
(CLAMS) technique was not significantly different among groups
Figure 1. Schematic of Fat Transplantation Groups
Visceral (VIS; epididymal) or subcutaneous (SC; flank) fat from donor mice
expressing whole-body green fluorescent protein (GFP) was transplanted
into the VIS or SC area of wild-type C57BL/6 host mice. The sham group
had surgery in the VIS or SC area, but no fat was transplanted.Cell Metabolism 7, 410–420, May 2008 ª2008 Elsevier Inc. 411
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VIS-VIS, SC-SC, and SC-VIS groups respectively in cohort 2).
The difference in body weight was also not due to levels of
energy expenditure because these levels were not significantly
different among the sham and transplantation groups during
the light and dark cycles (Figure 2G). Simple regression analyses
indicated that neither lean mass nor fat mass correlated with
total energy expenditure (r2 = 0.0002 and r2 = 0.003, respectively)
(StatView version 5.0.1, SAS Institute Inc.). Thus, lean mass and
Figure 2. Body Weight, Body Composition,
Energy Expenditure, and Respiratory
Quotient after Fat Transplantation
(A and B) In cohorts 1 and 2, body weight gain was
similar or higher after VIS fat transplantation, lower
after SC-SC fat transplantation, and lowest in the
SC-VIS group in comparison to the sham group.
(C) Fat mass was similar between the sham and
VIS transplantation groups, reduced in the SC-
SC group, and most reduced in the SC-VIS group.
(D) Percent body fat was significantly lower only in
the SC-VIS group as compared to the shamgroup.
(E and F) Lean mass (E) and percent lean mass (F)
were significantly higher in the SC-VIS group in
comparison to the sham group.
(G) Total energy expenditure (TEE; data not
shown) and TEE divided by lean mass were not
significantly different among all sham and trans-
plantation groups during the light and dark cycles.
(H and I) Respiratory quotient (RQ) was signifi-
cantly higher in the SC-VIS group than in the
sham group during the light and dark cycles (H)
and at almost all 30 min intervals during the 24 hr
measurement period (I), indicating a higher pro-
portion of carbohydrate to fat oxidation in the
SC-VIS group.
All data are presented as mean ± SEM. * denotes
statistical significance at p < 0.05.
fat mass did not have an independent
impact on energy expenditure.
Respiratory quotient (RQ) is the ratio
between carbon dioxide production and
oxygen consumption, which is an indica-
tor of the relative level of carbohydrate
and fat oxidation in the whole body. RQ
was significantly higher in the SC-VIS
group than in the sham group by 5.9%
during the light cycle (p < 0.05), by 7.0%
during thedarkcycle (p<0.05) (Figure2H),
and at almost all 30 min intervals through-
out the 24 hr measurement period (Fig-
ure 2I), indicating a higher proportion of
carbohydrate to fat metabolism in the
SC-VIS group. Otherwise, activity level,
heat production, andwater intake asmea-
suredbyCLAMSwerenot significantlydif-
ferent among the sham and transplanted
fat groups (data not shown). Overall, the
SC-VIS group had significantly improved
metabolism in terms of decreased body
weight, decreased percent body fat, and increased percent lean
mass, and this was associated with an increased proportion of
carbohydrate to fat metabolism without significant changes in
total energy expenditure or heat production.
Plasma Levels and Glucose and Insulin Tolerance Tests
At 9 weeks after transplantation, the levels of plasma glucose,
insulin, leptin, and adiponectin were assessed, and these
showed a pattern similar to that of body weight and fat mass.412 Cell Metabolism 7, 410–420, May 2008 ª2008 Elsevier Inc.
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VIS-VIS, and VIS-SC groups at 145–150 mg/dl, were slightly
but significantly decreased (6%) in the SC-SC group
(p < 0.05), and were even more significantly decreased by 15%
when SC fat was transplanted to the VIS cavity (SC-VIS)
(p < 0.01) (Figure 3A). Plasma insulin levels paralleled glucose
levels and were similar among the sham, VIS-VIS, and VIS-SC
groups (850 pg/ml), decreased by 26% in the SC-SC group,
and decreased by 33% in the SC-VIS group when compared
to the sham group, although these differences did not reach sta-
tistical significance. Thus, adding SC fat to a normal mouse
resulted in decreased glucose levels with normal or decreased
insulin levels, suggesting improved insulin sensitivity. These
metabolic improvements were greatest when the SC fat was
transplanted to the VIS cavity and were specific to the addition
of SC fat. Adding VIS fat to the VIS cavity had no effect on
body weight gain, body composition, or glucose or insulin levels.
Plasma leptin levels were not significantly different among the
sham, VIS-VIS, VIS-SC, and SC-SC groups but were signifi-
cantly decreased by 70% in the SC-VIS group in comparison
to sham controls (p < 0.05). The low leptin levels in the SC-VIS
group correlate with the lower fat mass in this group. Total
Figure 3. Basal Plasma Levels of Hormones
and Substrates, Glucose Tolerance Test,
and Insulin Tolerance Test after Fat
Transplantations in Cohort 1
(A) Basal plasma glucose and insulin levels were
not significantly different among the VIS transplan-
tation and sham groups, were lower in the SC-SC
group, and were lowest in the SC-VIS group.
Plasma leptin and total adiponectin levels also
had a decreasing pattern, with levels being highest
in the sham group and significantly lowest in the
SC-VIS group.
(B) Plasma samples were electrophoresed
through nonreducing SDS gels, transferred to
membranes, and probed with rabbit anti-mouse
adiponectin antibody. Percent of high molecular
weight (HMW) adiponectin to total adiponectin
(i.e., HMW + medium molecular weight [MMW] +
low molecular weight [LMW]) was not significantly
different among the groups.
(C) Left: after a 2 hr fast for the glucose tolerance
test, glucose was administered intraperitoneally.
Glucose levels at 120 min were significantly lower
only in the SC-VIS group as compared to the sham
group. Right: after an overnight fast for the insulin
tolerance test, insulin was injected intraperitone-
ally. No significant difference in blood glucose
levels was observed among the groups.
All data are presented as mean ± SEM. * denotes
statistical significance at p < 0.05.
plasma adiponectin levels were similar
between the sham and VIS-VIS groups,
significantly decreased by 12% in the
VIS-SC and SC-SC groups (p < 0.05),
and decreased by 25% in the SC-VIS
group (p < 0.01) in comparison to the
sham group. Higher levels of high molec-
ular weight (HMW) adiponectin in relation to total adiponectin,
but not absolute total adiponectin levels, correlate better with
improved insulin sensitivity (Pajvani et al., 2004). However, the
percent of HMW adiponectin to total adiponectin was not signif-
icantly different among the sham and transplantation groups
(Figure 3B). Since adiponectin levels in the SC-VIS group were
either decreased or similar to that of the sham group, it is unlikely
that adiponectin can account for the decreased body weight or
fat mass in this group.
At 10 weeks after transplantation, intraperitoneal glucose
tolerance tests (GTTs) were performed in the mice. Most notable
was the SC-VIS group, which had the lowest glucose levels in
comparison to the sham group, and this reached statistical
significance at 120 min after administration of the glucose load
(p < 0.05) (Figure 3C). In the remaining groups, blood glucose
levels during the 120 min period tended to be highest in the VIS-
VIS group, similar to the sham group in the VIS-SC group, and
lower in the SC-SC group, although these differences did not
reach statistical significance. Thus, addingSC fat to the VIS cavity
significantly improved glucose tolerance, whereas adding VIS fat
to the VIS cavity tended to cause, if anything, a deterioration of
glucose tolerance. Intraperitoneal insulin tolerance tests (ITTs)Cell Metabolism 7, 410–420, May 2008 ª2008 Elsevier Inc. 413
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difference among the groups, although at 120 min, the SC-SC
group tended to have lower glucose levels than the other groups.
Insulin Sensitivity by Hyperinsulinemic-Euglycemic
Clamp
To more precisely and directly assess insulin sensitivity, we uti-
lized the hyperinsulinemic-euglycemic clamp technique coupled
with D-[3-3H]glucose and [14C]deoxyglucose infusions. This
allowed assessment of three different parameters of glucose
metabolism: (1) whole-body insulin sensitivity, (2) glucose uptake
intomuscle and endogenous and transplanted fat, and (3) effects
of insulin on hepatic glucose output. These hyperinsulinemic-
euglycemic clamps were performed at 12 weeks after transplan-
tations in cohort 2.
Direct measurement of whole-body insulin sensitivity was
quantified during the hyperinsulinemic-euglycemic clamp as
the amount of exogenous glucose infusion required to maintain
Figure 4. Direct Measures of Insulin Sen-
sitivity by Hyperinsulinemic-Euglycemic
Clamp after Fat Transplantation in Cohort 2
(A) Whole-body insulin sensitivity as quantified by
glucose infusion rate (GIR) was not significantly
different among the sham, VIS-VIS, and SC-SC
groups but was significantly higher in the SC-VIS
group.
(B) Insulin-stimulated [14C]deoxyglucose (14C-
DG) uptake was similar between endogenous
VIS fat and endogenous SC fat in the sham group.
14C-DG uptake in the fat grafts was not signifi-
cantly different in the three transplantation groups
and had at least the same level of 14C-DG uptake
as endogenous fat.
(C) 14C-DG uptake into endogenous SC fat of host
mice was greater in the SC-SC and SC-VIS groups
in comparison to the sham and VIS-VIS groups.
(D) 14C-DG uptake into endogenous VIS fat of the
sham and transplantation groups was not signifi-
cantly different.
(E) Hepatic glucose production (HGP) in the basal
state was not significantly different among the
groups, with a trend for the lowest levels in the
SC-VIS group in comparison to the sham group.
As expected, during the clamp, insulin decreased
HGP in the sham and VIS-VIS groups in compari-
son to their corresponding basal HGP levels and,
more importantly, further decreased HGP in the
SC-SC and SC-VIS groups.
(F) The greatest percent suppression of HGP dur-
ing the hyperinsulinemic clamp with respect to the
basal level was seen in the SC-SC and SC-VIS
groups.
(G) Glucose uptake in muscle was not significantly
different among the groups.
All data are presented as mean ± SEM. * denotes
statistical significance at p < 0.05.
blood glucose levels at initial fasting
levels during the hyperinsulinemic infu-
sion and expressed as glucose infusion
rate (GIR). GIRwas not significantly differ-
ent between the sham and VIS-VIS
groups (Figure 4A). However, GIR was significantly increased
by 2.0-fold when SC fat was transplanted to the SC area and
had an even greater increase to 2.4-fold when SC fat was trans-
planted to the VIS area in comparison to GIR in the sham group
(p < 0.05). Hence, increasing SC fat in the SC depot and, more
strikingly, increasing SC fat in the VIS depot improved whole-
body insulin sensitivity as measured by GIR in response to a
stable insulin infusion.
Insulin-stimulated glucose uptake into transplanted fat depots
and endogenous fat and muscle was assessed during the final
45 min of the hyperinsulinemic-euglycemic clamp using [14C]
deoxyglucose. In the sham group, [14C]deoxyglucose uptake
was similar in endogenous SC fat and VIS fat (Figure 4B), i.e.,
there was no intrinsic difference in glucose uptake between the
SC and VIS fat depots in the control animals of this study. All
fat grafts in the three transplantation groups had at least the
same level of glucose uptake as the endogenous SC and VIS
fat in the sham group (Figure 4B). In the transplanted fat grafts414 Cell Metabolism 7, 410–420, May 2008 ª2008 Elsevier Inc.
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the VIS-VIS group and tended to be higher in the SC-SC and
SC-VIS groups, although these changes were not statistically
significant. In fact, glucose uptake in the fat grafts averaged
1.4- to 5.7-fold higher than that in the fat in the sham group, fur-
ther indicating good vascularization and function of the trans-
planted fat grafts (Figure 4B) and thereby confirming the success
of the fat transplantation. Most interestingly, [14C]deoxyglucose
uptake into endogenous SC fat of the recipient mice was signif-
icantly increased by 2.5- to 2.8-fold in the groups with SC fat
transplanted into either the SC or VIS depots (SC-SC and
SC-VIS) in comparison to the sham group (p < 0.05), whereas
endogenous SC fat in the group with VIS fat transplanted into
the VIS cavity had levels of glucose uptake similar to the fat in
the sham group (Figure 4C). These results suggest crosstalk
between SC fat grafts and endogenous SC fat, regardless of
whether the SC fat graft is transplanted into the SC area or the
VIS cavity. By contrast, [14C]deoxyglucose uptake into endoge-
nous VIS fat was not different among the sham and transplant-
ation groups (Figure 4D).
Hepatic glucose production (HGP) was assessed both in the
basal state and during the insulin clamp (Figure 4E). Basal
HGP was not significantly different between the groups,
although it tended to be decreased in the SC-VIS group in com-
parison to the sham group. Insulin infusion during the clamp
decreased HGP in the sham and VIS-VIS group as expected,
but more interestingly, the decrease was greatest in the SC-SC
andSC-VIS groups. In the shamand VIS-VIS groups, insulin sup-
pression of HGP was 52% ± 18% and 71% ± 36%, respectively,
as compared to these groups’ corresponding basal HGP levels
(Figure 4F). Consistent with the improved insulin sensitivity, insu-
lin suppression of HGP was greatest in the groups with SC fat
transplantation, with 97%± 2% suppression in the SC-SC group
and 100% ± 0% suppression in the SC-VIS group. [14C]deoxy-
glucose uptake in muscle was not significantly different among
the groups (Figure 4G). Thus, the addition of SC fat to a normal
mouse via transplantation enhanced insulin sensitivity in the
liver, as well as in endogenous SC fat. In all cases, this effect
was observed when SC fat was added to the SC area but was
most pronounced when SC fat was added to the VIS cavity. By
contrast, addition of VIS fat to the VIS cavity neither improved
nor worsened insulin sensitivity.
Histology and Markers of Inflammation
At 12 weeks after fat transplantation, the recipient mice were
sacrificed, and the endogenous fat and exogenous fat grafts,
as identified by presence of GFP, were removed for histological
examination. In cohort 2, hematoxylin and eosin (H&E) staining of
endogenous visceral/epididymal and subcutaneous/flank fat
pads of the recipient mice showed normal-appearing signet
rings of fat cells, with occasional interspersed macrophages
and vascular cells. The transplanted fat allografts had normal
histology in comparison to endogenous SC and VIS fat in the
sham group (Figure 5A). The mean area of adipocytes in the
VIS depot appeared to be 20% larger than that of the SC depot
in the sham group, but this was not statistically significant
(Figure 5B, first and third columns). Adding VIS fat to the VIS
cavity (VIS-VIS) did not significantly change the mean area of
transplanted adipocytes in comparison to endogenous VISadipocytes in the sham group (Figure 5B, first and second
columns). Adding SC fat to the SC area (SC-SC) tended to de-
crease the average adipocyte size in comparison to endogenous
SC fat in the sham group, but this also did not reach statistical
significance. Remarkably, transplantation of SC fat into the VIS
cavity (SC-VIS) significantly decreased average adipocyte area
by 38%compared to adipocytes in the endogenous SC fat depot
and, more importantly, did not increase these adipocytes’ size to
that of the surrounding endogenous VIS fat. Vascularization in
the transplanted GFP fat grafts was observed in whole mounts
of fat, further confirming the viability of the fat grafts
(Figure 5C). Levels of macrophages and inflammation were
quantitated by mRNA levels of the macrophage cell surface
marker F4/80 (Emr1) and the cytokines interleukin-6 (Il6) and
tumor necrosis factor a (Tnf) using real-time qRT-PCR. While
all of the transplanted fat had minimally increased levels of
mRNAs for F4/80, Il6, and Tnf, this was significant only in VIS
fat transplanted into the VIS depot (VIS-VIS) (Figure 5D). Thus,
as expected, the syngeneic transplant of fat resulted in little, if
any, rejection or inflammatory reaction.
Gene Expression
To further assess the status of the adipose tissue graft and
explore the potential mechanisms by which the adipose graft
might affect whole-body metabolism, expression of several fat-
relatedmolecules, specifically peroxisome proliferator-activated
receptor g (Pparg), fatty acid synthase (Fas), leptin, adiponectin,
resistin, and retinol-binding protein 4 (Rbp4), was analyzed.
Since it was not possible to isolate enough fat cells from the
transplanted fat in each mouse for this analysis, the entire trans-
plant or endogenous fat pad was used, and the data were
expressed in terms of both absolute mRNA levels and mRNA
levels relative to fatty acid binding protein 4 (Fabp4, also known
as aP2) levels, as a marker for the amount of differentiated fat
cells present in the tissue. The patterns for absolute gene
expression levels and gene expression levels relative to Fabp4
levels were similar.
This analysis revealed that adding VIS fat to the VIS area
(VIS-VIS) did not significantly change gene expression levels of
Pparg, Fas, leptin, or adiponectin in the fat grafts as compared
to levels in the endogenous VIS fat in the sham group but did
change resistin and Rbp4 levels, which were 52% and 65%
lower, respectively, in fat grafts than in endogenous VIS fat in
the sham group (p < 0.01) (Figure 6, first and second columns
of graphs). Also, adding more SC fat to the SC area (SC-SC)
did not significantly change gene expression levels of the six
adipocyte marker genes as compared to endogenous SC fat in
the sham group (Figure 6, third and fourth columns of graphs).
Thus, adding more fat of the same depot did not significantly
change relative gene expression of Pparg, Fas, leptin, or adipo-
nectin in either SC or VIS fat grafts. Adding SC fat to the SC area
also did not significantly change gene expression of resistin or
Rbp4 in SC fat grafts. However, adding VIS fat to the VIS cavity
significantly decreased gene expression of resistin and Rbp4 in
VIS fat grafts. When SC fat was transplanted to the VIS area
(SC-VIS), gene expression levels for Pparg, Fas, leptin, and
Rbp4 were also not significantly different from any other group,
although the gene expression levels in SC-VIS fat grafts showed
considerable variability. Interestingly, adiponectin, resistin, andCell Metabolism 7, 410–420, May 2008 ª2008 Elsevier Inc. 415
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(SC-VIS) were decreased by 2.6-, 2.2-, and 6.7-fold, respec-
tively, compared to the endogenous SC fat in the sham group
(p < 0.01, p < 0.05, p = 0.29). These low gene expression levels
for adiponectin and leptin are consistent with the lower levels of
adiponectin and leptin in the plasma of the SC-VIS group.
Overall, these analyses of gene expression levels showed that
(1) the transplanted fat grafts in the VIS-VIS, SC-SC, and SC-VIS
transplantation groups expressed Pparg and Fas mRNA levels
that were not significantly different from those of endogenous
VIS or endogenous SC fats in the sham group; (2) adding
more fat of the same depot (VIS-VIS or SC-SC) did not change
gene expression levels of Pparg, Fas, leptin, or adiponectin
but did change levels of resistin and Rbp4 when VIS fat was
added to the VIS cavity; and (3) adding SC fat to the VIS cavity
lowered mRNA levels of leptin, adiponectin, and resistin, but not
Pparg, Fas, or Rbp4, in comparison to levels in endogenous
SC fat.
Figure 5. Histology and Inflammatory
Markers in Transplanted and Endogenous
Fat in Cohort 2
(A) Hematoxylin and eosin (H&E) staining of VIS
and SC fat pads was performed in all groups of
cohort 2. Transplanted VIS and SC fat pads had
normal histology in comparison to endogenous
VIS and SC fat pads in the sham group as shown
at 4003 magnification.
(B) Area of adipocytes was measured on the H&E
slides with ImageJ software. Transplanting SC
fat into the visceral cavity (SC-VIS) significantly
decreased the mean area of the adipocytes in
comparison to that of the endogenous SC fat in
the sham group.
(C) Whole mount of a transplanted fat graft
expressing GFP viewed under ultraviolet light.
Arrows indicate sites of vascularization in the fat
graft.
(D) Presence of macrophages and inflammatory
markers was assessed by quantifying mRNA
levels of the macrophage cell surface marker
F4/80 (Emr1) and the inflammatory cytokines Il6
and Tnf by real-time qRT-PCR. mRNA levels in
VIS-VIS fat grafts were significantly higher than
those in endogenous VIS fat in the sham group.
There were no significant differences in macro-
phages, Il6, or Tnf among the SC-SC and SC-VIS
fat grafts and the endogenous fat pads.
All data are presented as mean ± SEM. * denotes
statistical significance at p < 0.05.
DISCUSSION
The differential physiological effects and
risk of metabolic disease of visceral (cen-
tral) versus subcutaneous (peripheral)
obesity havebeendocumented inmultiple
epidemiological and physiological studies
(Carey et al., 1997; Wang et al., 2005;
Nicklas et al., 2006; Ross et al., 2007;
Misra et al., 1997; Snijder et al., 2003;
Tanko et al., 2003). We have further inves-
tigated mechanisms by which subcutaneous and visceral fat
cause contrasting metabolic profiles by transplanting fat from
both SC and VIS depots to both SC and VIS areas. The fat trans-
plantations were successful as confirmed by normal histology of
fat and no significant differences in number of macrophages or
levels of the inflammatory molecules Il6 and Tnf, except for the
group with visceral fat added to the visceral cavity. Furthermore,
the fat grafts had a high uptake of [14C]deoxyglucose, indicating
reestablished vascularization, as well as no significant changes
inmRNA levels ofPpargandFas in comparison to thoseof endog-
enous SC and VIS fat in the sham-operated mice.
Remarkably, we found that when SC fat was transplanted into
the VIS cavity (SC-VIS), mice exhibited decreased body weight,
total fat mass accumulation, and adipocyte cell size despite no
change in food intake, total energy expenditure, activity level,
or heat production. However, small effects on body weight, fat,
and lean mass in the SC-VIS group, which took 8–12 weeks to
become observable, may have made the mechanisms difficult416 Cell Metabolism 7, 410–420, May 2008 ª2008 Elsevier Inc.
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showed improved glucose homeostasis, including decreased
plasma glucose and insulin levels, and improved glucose
tolerance compared to sham-operated mice. The improved
metabolic effects in the SC-VIS group were confirmed by hyper-
insulinemic-euglycemic clamp, which revealed increased insulin
sensitivity as measured by three parameters, namely increased
whole-body glucose uptake as measured by glucose infusion
rate, increased glucose uptake in endogenous SC fat, and in-
creased insulin suppression of hepatic glucose production.
These metabolic effects were specific to transplantation of SC
fat and were greatest when SC fat was transplanted into the
VIS cavity but were not observed following transplantation of
VIS fat into the VIS cavity. Thus, there are specific beneficial
metabolic effects of transplanting SC fat to the VIS area.
Figure 6. Gene Expression in Endogenous and Transplanted Fat
Gene expression was measured by real-time qRT-PCR and expressed in
terms of mRNA levels relative to Fabp4 (aP2). Analyses of the fat-related
molecules Pparg, Fas, leptin, adiponectin, resistin, and Rbp4 show that (1)
transplanted VIS-VIS, SC-SC, and SC-VIS fat grafts express Pparg and Fas
mRNA levels that are not significantly different from those of endogenous
VIS or endogenous SC fats in the sham group; (2) adding more fat of the
same depot (VIS-VIS or SC-SC) does not change gene expression levels of
the fat genes analyzed, except for resistin and Rbp4 in the VIS-VIS group;
and (3) adding SC fat to the VIS cavity (SC-VIS) lowers mRNA levels of leptin,
adiponectin, resistin, and Rbp4 in comparison to levels in the endogenous VIS
and SC fat depots in the sham group. All data are presented as mean ± SEM.
* denotes statistical significance at p < 0.05.Successful transplantations of adipocytes and whole fat pads
to the SC area in mice have been previously reported (Green and
Kehinde, 1979; Gavrilova et al., 2000). However, transplantations
of mature adipocytes into the VIS cavity have been less success-
ful (Rieck and Schlaak, 2003). Recently, Konrad et al. (2007)
successfully transplanted the whole visceral fat pad into the vis-
ceral cavity by stitching epididymal fat to the side of the perito-
neal cavity. However, in contrast to our results and those of
epidemiological studies, in the Konrad et al. study this appeared
to improve insulin sensitivity. Visceral fat in humans drains por-
tally, but the intra-abdominal fat grafts in the Konrad et al. study
likely drained into the adjacent systemic circulation. In our study,
when visceral fat was added to the visceral cavity (VIS-VIS), there
were multiple sites of engraftment, in which the graft was mixed
with epididymal fat next to mesenteric fat and under the liver.
Thus, in our case, there was likely both portal and systemic
drainage. Further studies are needed to determine whether the
amount of visceral fat or the balance between portal and sys-
temic drainage is more important for insulin sensitivity. A recent
online publication (Hocking et al., 2008) in which transplantation
of SC fat into the intra-abdominal space by suturing to the
visceral side of the peritoneum had a protective effect on adipos-
ity and glucose tolerance by intraperitoneal GTT confirmed some
of our results.
The beneficial metabolic effect of SC fat transplantation into
the VIS depot versus VIS fat transplantation into the VIS depot
indicates that SC fat tissue must have some cell-autonomous
properties that can act on other tissues to improve insulin sensi-
tivity andmetabolic state. This effect was observed regardless of
whether SC fat was transplanted to the SC area or the VIS cavity
but was greatest in the intra-abdominal transplant group. These
findings are consistent with other studies, which have shown
persistent differences in gene expression profiles, degree of
cell proliferation, capacity to differentiate, and lipid content dur-
ing in vitro culture of SC versus VIS fat cells obtained from
humans and mice, thereby indicating cell-autonomous proper-
ties of SC and VIS fat cells (Tchkonia et al., 2007; Gesta et al.,
2006). Determining exactly what these cell-autonomous proper-
ties of SC fat are will require further study. Furthermore, evidence
for crosstalk between various organs and adipose tissue has
been demonstrated by several studies. For example, mice with
a muscle-specific inactivation of the insulin receptor exhibit an
increase in glucose uptake in fat and an increase in fat pad
size (Bru¨ning et al., 1998). Conversely, specific impairment of
glucose transporter 4 (GLUT4) in adipose tissue results in de-
creased glucose uptake into muscle, possibly as a result of
altered release of specific molecules from fat (Abel et al.,
2001). Thus, our findings of crosstalk specifically between SC
fat graft, liver, and other adipose tissue depots are of consider-
able interest, and the possible mechanisms need to be eluci-
dated.
What is clear is that these effects cannot be explained by dif-
ferences in inflammatory cytokines or the best known adipo-
kines. Inflammatory cells and molecules, such as macrophages,
TNFa, and IL-6, have been observed at high levels in obese sub-
jects and have been associated with insulin resistance and de-
velopment of type 2 diabetes (Weisberg et al., 2003). However,
in our fat transplantation model, levels of Il6, Tnf, and F4/80 in
the transplanted SC fat grafts were not significantly differentCell Metabolism 7, 410–420, May 2008 ª2008 Elsevier Inc. 417
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possibility that other inflammatory pathways and molecules
play an important role in the improved metabolic effect in this
model has not been ruled out yet. Second, adipokines, such as
high levels of leptin and adiponectin or low levels of RBP4, can
favorably affect food intake, insulin sensitivity, glucose and lipid
metabolism, and inflammation. However, our results indicate
that both plasma levels and gene expression of leptin, total adi-
ponectin, and percent HMW adiponectin in endogenous and
transplanted fat were lower or unchanged in the SC-VIS trans-
plantation group, which had improved metabolic effects when
compared to the sham group. Thus, although these adipokines
may be important in models of obesity, they are not likely
candidates to explain the improved metabolic effects in our
transplantation model. Interestingly, gene expression levels of
the adipokines resistin and Rbp4 were lower in the fat grafts of
the SC-VIS group, in agreement with studies reporting an inverse
relationship between resistin or RBP4 and insulin sensitivity.
However, the mechanism by which low levels of resistin could
lead to improvedmetabolic effects requires further investigation.
Gene expression levels of Rbp4 in the fat grafts of the SC-VIS
group were not significantly different from those of the sham
group but appeared to be lower and could potentially play
a role in the increased insulin sensitivity. Overall, mechanisms
to explain the beneficial metabolic effects of transplanting SC
fat into the VIS cavity do not seem to involve inflammatory
molecules such as macrophages, TNFa, and IL-6 or known
adipokines such as leptin and adiponectin; nevertheless, resis-
tin, RBP4, and other still unrecognized adipokines are possible
routes of further exploration.
In conclusion, using an in vivo fat transplantation strategy, we
have demonstrated that subcutaneous adipose tissue can have
direct and beneficial effects on control of body weight and me-
tabolism. These effects appear to be due to a cell-autonomous
property of the SC fat, most likely secretion of one or more fac-
tors that can mediate improvements in the metabolic profile. Our
results show that SC fat can crosstalk with other fat tissues and
liver to bring about improved metabolic effects. The degree to
which SC fat ameliorates metabolic state was greatest when
SC fat was placed in the visceral cavity, suggesting that it is im-
portant for secreted factors or other factors associated with SC
fat to be close to or present at a high enough concentration next
to the VIS fat or liver in order to mediate the greatest metabolic
improvement. Identification and investigation of these secreted
factors or other factors associated specifically with SC fat may
provide new targets for the treatment and/or prevention of
obesity-related complications and diseases such as insulin
resistance, the metabolic syndrome, cardiovascular disease,
and diabetes.
EXPERIMENTAL PROCEDURES
Mice and Fat Transplantation
Twelve-week-old male C57BL/6 mice were used as recipients. In cohort 1,
10-week-old male mice of the same strain were used as donors. In cohort 2,
C57BL/6 mice carrying GFP as a transgene on the b-actin promoter (Actb)
were used as donors (stock #003291, The Jackson Laboratory). Since this
transgene was expressed in all tissues of the donor mice, it was possible to
identify the transplanted fat in the recipient mice using ultraviolet illumination.
All animals weremaintained on a standardmouse diet (9F 5020 Lab Diet, Phar-418 Cell Metabolism 7, 410–420, May 2008 ª2008 Elsevier Inc.maServ, Inc.) and a standard 12 hr light/dark cycle. The Joslin Diabetes Center
Institutional Animal Care and Use Committee approved all experiments.
Fat transplantation was performed using fat pads removed from either the
subcutaneous flank area or the intra-abdominal perigonadal (epididymal)
area. After cervical dislocation of donor mice, fat pads were removed, cut
into approximately 200 mg slices, and kept in saline in 50 ml tubes placed in
37C water bath until transplantation. Recipient mice were anesthetized by in-
traperitoneal injection with 0.015 ml/kg of a 2.4% solution of 1:1 mixture of
2,2,2-tribromoethanol and t-amyl alcohol. For each recipient mouse, a total
of 1.0 g of donor slices of fat were transplanted into the visceral (VIS) area,
i.e., the maximum amount of fat graft that could fit in the intra-abdominal cavity
was carefully lodged deep between folds within sliced portions of endogenous
epididymal fat of the recipient and lodged next to the mesenteric fat just below
the liver, or transplanted into the subcutaneous (SC) area, i.e., below the skin
on the back of the recipient. Five groups ofmicewere studied: two in which VIS
epididymal fat was transplanted into the VIS cavity (VIS-VIS) or the SC area
(VIS-SC), two in which SC flank fat was transplanted into the SC area
(SC-SC) or the VIS cavity (SC-VIS), and one in which mice underwent surgery
but no fat was added (sham) (Figure 1). Cohort 1 was used to measure body
weight, body composition, basal plasma levels, glucose tolerance test
(GTT), and insulin tolerance test (ITT), and the sample size was n = 8, 5, 7, 7,
and 8 mice in the respective groups listed above. Cohort 2 (not including the
VIS-SC group) was used for CLAMS studies, hyperinsulinemic-euglycemic
clamp studies, histological analyses, and gene expression data, and the
sample size was n = 7, 3, 5, and 5 mice, respectively.
Biochemical and Physiological Methods
In cohort 2, histological H&E-stained sections of fat were prepared after fixa-
tion in 10% phosphate-buffered formalin. To measure the size of adipocytes,
at least 300 cells per H&E-stained sample were analyzed using NIH ImageJ
software (http://rsb.info.nih.gov/ij/). To assess the presence of macrophages
and inflammatory markers, mRNA levels of the macrophage cell surface
marker F4/80, Il6, and Tnfwere measured by real-time qRT-PCR as described
previously (Gesta et al., 2006). mRNA expression levels of the fat-related
genes Fabp4, Pparg, Fas, leptin, adiponectin, resistin, and Rbp4 in endoge-
nous and transplanted fat grafts were also measured by real-time qRT-PCR.
To assess metabolic effects of fat transplantation, body weight and compo-
sition were measured. Fat and leanmass weremeasured by dual-energy X-ray
absorptiometry (DEXA) scanning. The Comprehensive Lab Animal Monitoring
System (CLAMS) method was used to measure activity level, food and water
intake, volume of O2 consumption, volume of CO2 production, and heat
production 10 weeks after fat transplantation (Oxymax OPTO-M3 system,
Columbus Instruments). Total energy expenditure of mice was calculated as
described previously (Albarado et al., 2004). Plasma levels of hormones and
metabolites were assessed by blood obtained by tail vein sampling after a
2 hr fast from 9 to 11 a.m. Basal glucose wasmeasured with an Elite OneTouch
glucometer (Bayer). Plasma insulin, leptin, and total adiponectin were mea-
sured with mouse ELISA kits (Crystal Chem Inc. and Alpco Diagnostics).
HMW adiponectin levels were measured as described previously (Coenen
et al., 2007) with a 6% nonreducing SDS gel, rabbit anti-adiponectin antibody
(BioVendor) at a 1:2,000 dilution, and secondary antibody at a 1:10,000 dilu-
tion. GTT was performed after an overnight fast from 6 p.m. to 9 a.m. using
an intraperitoneal injection of 20% dextrose solution at a dose of 2.0 g/kg
body weight. ITT was performed after a 2 hr fast from 9 to 11 a.m. using an in-
traperitoneal injection of 1.25 U of insulin (Novolin regular human insulin, Novo
Nordisk) per kg body weight. Insulin sensitivity was directly andmore precisely
assessed by performing hyperinsulinemic-euglycemic clamps to measure
whole-body insulin sensitivity and fat- and muscle-specific glucose uptake
as described previously by Norris et al. (2003), except that a continuous insulin
infusion dose of 5 mU/kg/min was used and blood glucose was maintained at
115 mg/dl during the clamp. Hepatic glucose production (HGP) was assessed
by subtraction of the glucose infusion rate (GIR) from whole-body glucose
turnover as measured with D-[3-3H]glucose (Finegood et al., 1988).
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